MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

We analysed the prognostic significance of minimal residual disease (MRD) level in adult patients with acute myeloid leukemia (AML) treated in the randomized gemtuzumab ozogamicin (GO) ALFA-0701 trial. Levels of WT1 and NPM1 gene transcripts were assessed using cDNA-based real-time quantitative PCR...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Lambert, Juliette, Lambert, Jérôme, Nibourel, Olivier, Pautas, Cécile, Hayette, Sandrine, Cayuela, Jean-Michel, Terré, Christine, Rousselot, Philippe, Dombret, Hervé, Chevret, Sylvie, Preudhomme, Claude, Castaigne, Sylvie, Renneville, Aline
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2014
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171629/
https://ncbi.nlm.nih.gov/pubmed/25026287
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk